Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03628235 · ClinicalTrials.gov registry record

HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States

A clinical trial, sponsored by CHDI Foundation.

Completed
Registry status
233
Enrollment target

NCT03628235 is a clinical trial that has completed, run by CHDI Foundation. The registered enrollment target is 233 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03628235 has completed, sponsored by CHDI Foundation.

COMPLETED
Registry status
233 participants
Enrollment target

Study Summary

Huntington's disease (HD) is a rare, inherited and progressive neurodegenerative disorder for which hallmark symptoms include movement disorders, loss of cognitive faculties and psychiatric disturbances. With the progression of the disease, patients require increasing level of medical care, caregiver support, and long-term care, which lead to substantial burden of illness. Very little data are available on the direct or indirect costs for HD. The direct medical costs of HD in the US have been summarized from retrospective commercial and Medicaid claims data analysis. The indirect and out-of-pocket costs of HD in the US have not been quantified. This study will help to bridge these gaps. This study is a single-assessment, cross-sectional online survey administered to Huntington disease gene expansion carriers (HDGECs) and companions of HDGECs by HD stage to understand the indirect and out-of-pocket costs of Huntington's disease in the US.

Interventions

  • BEHAVIORAL Online survey

Trial Details

FieldValue
Enrollment Target 233 participants
Start Date 2020-06-21
Est. Completion 2022-06-21

Sponsor

CHDI Foundation

5 total trials

What the Registry Record Tells You About NCT03628235

The ClinicalTrials.gov registry entry for NCT03628235 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CHDI Foundation, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Online survey is the first listed.

NCT03628235 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03628235 about?

NCT03628235 is a clinical study titled "HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States". Huntington's disease (HD) is a rare, inherited and progressive neurodegenerative disorder for which hallmark symptoms include movement disorders, loss of cognitive faculties and psychiatric disturbances. With the progression of the disease, patients require increasing level of medical care, caregive...

What is the current status of trial NCT03628235?

This trial is currently completed. The enrollment target is 233 participants. The study started on 2020-06-21. Estimated completion is 2022-06-21.

What interventions are being tested in trial NCT03628235?

The interventions under investigation include: Online survey (BEHAVIORAL).

Who is sponsoring clinical trial NCT03628235?

This trial is sponsored by CHDI Foundation, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.